Is myeloablative dose intensity necessary in allogeneic hematopoietic cell transplantation for lymphomas?
Mohamed A. Kharfan‐Dabaja(Jacksonville College), Mehdi Hamadani(Medical College of Wisconsin), Ernesto Ayala(Mayo Clinic in Florida), Najla El‐Jurdi(University Hospitals of Cleveland), Abraham S. Kanate(HonorHealth), Bipin N. Savani(Vanderbilt University Medical Center)
Cited by 19
Related Papers
Current Use of and Trends in Hematopoietic Cell Transplantation in the United States
|Transplantation and Cellular Therapy|2020|718
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes
|Journal of Clinical Oncology|2017|664
Early cytomegalovirus reactivation remains associated with increased transplant-related mortality in the current era: a CIBMTR analysis
|Blood|2016|554
Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: a new classification from the European Society for Blood and Marrow Transplantation
|Bone Marrow Transplantation|2016|538
Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma
|New England Journal of Medicine|2021|532